Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 51

1.

Proteasome inhibitors sensitize glioma cells and glioma stem cells to TRAIL-induced apoptosis by PKCε-dependent downregulation of AKT and XIAP expressions.

Kahana S, Finniss S, Cazacu S, Xiang C, Lee HK, Brodie S, Goldstein RS, Roitman V, Slavin S, Mikkelsen T, Brodie C.

Cell Signal. 2011 Aug;23(8):1348-57. doi: 10.1016/j.cellsig.2011.03.017.

PMID:
21440622
2.

Functional drug screening assay reveals potential glioma therapeutics.

Badr CE, Wurdinger T, Tannous BA.

Assay Drug Dev Technol. 2011 Jun;9(3):281-9. doi: 10.1089/adt.2010.0324.

3.

Towards novel paradigms for cancer therapy.

Pavet V, Portal MM, Moulin JC, Herbrecht R, Gronemeyer H.

Oncogene. 2011 Jan 6;30(1):1-20. doi: 10.1038/onc.2010.460. Review.

PMID:
20935674
4.

Real-time monitoring of nuclear factor kappaB activity in cultured cells and in animal models.

Badr CE, Niers JM, Tjon-Kon-Fat LA, Noske DP, Wurdinger T, Tannous BA.

Mol Imaging. 2009 Sep-Oct;8(5):278-90.

5.

Gaussia luciferase variant for high-throughput functional screening applications.

Maguire CA, Deliolanis NC, Pike L, Niers JM, Tjon-Kon-Fat LA, Sena-Esteves M, Tannous BA.

Anal Chem. 2009 Aug 15;81(16):7102-6. doi: 10.1021/ac901234r.

6.

The late stages of autophagy: how does the end begin?

Noda T, Fujita N, Yoshimori T.

Cell Death Differ. 2009 Jul;16(7):984-90. doi: 10.1038/cdd.2009.54. Review.

7.

Inhibition of the sodium potassium adenosine triphosphatase pump sensitizes cancer cells to anoikis and prevents distant tumor formation.

Simpson CD, Mawji IA, Anyiwe K, Williams MA, Wang X, Venugopal AL, Gronda M, Hurren R, Cheng S, Serra S, Beheshti Zavareh R, Datti A, Wrana JL, Ezzat S, Schimmer AD.

Cancer Res. 2009 Apr 1;69(7):2739-47. doi: 10.1158/0008-5472.CAN-08-2530.

8.

Mutant sodium channel for tumor therapy.

Tannous BA, Christensen AP, Pike L, Wurdinger T, Perry KF, Saydam O, Jacobs AH, García-Añoveros J, Weissleder R, Sena-Esteves M, Corey DP, Breakefield XO.

Mol Ther. 2009 May;17(5):810-9. doi: 10.1038/mt.2009.33.

9.

Identification of a molecular signaling network that regulates a cellular necrotic cell death pathway.

Hitomi J, Christofferson DE, Ng A, Yao J, Degterev A, Xavier RJ, Yuan J.

Cell. 2008 Dec 26;135(7):1311-23. doi: 10.1016/j.cell.2008.10.044.

10.

Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and Temozolomide.

Hingtgen S, Ren X, Terwilliger E, Classon M, Weissleder R, Shah K.

Mol Cancer Ther. 2008 Nov;7(11):3575-85. doi: 10.1158/1535-7163.MCT-08-0640.

11.

Novel therapeutic applications of cardiac glycosides.

Prassas I, Diamandis EP.

Nat Rev Drug Discov. 2008 Nov;7(11):926-35. doi: 10.1038/nrd2682. Review.

PMID:
18948999
12.
13.

Targeting the alpha 1 subunit of the sodium pump to combat glioblastoma cells.

Lefranc F, Mijatovic T, Kondo Y, Sauvage S, Roland I, Debeir O, Krstic D, Vasic V, Gailly P, Kondo S, Blanco G, Kiss R.

Neurosurgery. 2008 Jan;62(1):211-21; discussion 221-2. doi: 10.1227/01.NEU.0000311080.43024.0E.

PMID:
18300910
14.

A secreted luciferase for ex vivo monitoring of in vivo processes.

Wurdinger T, Badr C, Pike L, de Kleine R, Weissleder R, Breakefield XO, Tannous BA.

Nat Methods. 2008 Feb;5(2):171-3. doi: 10.1038/nmeth.1177.

15.

A highly sensitive assay for monitoring the secretory pathway and ER stress.

Badr CE, Hewett JW, Breakefield XO, Tannous BA.

PLoS One. 2007 Jun 27;2(6):e571.

16.

Use of APO2L/TRAIL with mTOR inhibitors in the treatment of glioblastoma multiforme.

Panner A, Parsa AT, Pieper RO.

Expert Rev Anticancer Ther. 2006 Sep;6(9):1313-22. Review.

PMID:
17020463
17.

New approaches to primary brain tumor treatment.

Sathornsumetee S, Rich JN.

Anticancer Drugs. 2006 Oct;17(9):1003-16. Review.

PMID:
17001172
18.

Cardiac glycosides provide neuroprotection against ischemic stroke: discovery by a brain slice-based compound screening platform.

Wang JK, Portbury S, Thomas MB, Barney S, Ricca DJ, Morris DL, Warner DS, Lo DC.

Proc Natl Acad Sci U S A. 2006 Jul 5;103(27):10461-6.

19.
20.

Phase 1 trial of Anvirzel in patients with refractory solid tumors.

Mekhail T, Kaur H, Ganapathi R, Budd GT, Elson P, Bukowski RM.

Invest New Drugs. 2006 Sep;24(5):423-7.

PMID:
16763787

Supplemental Content

Support Center